Mice were taken down 2 days after antibody dosing, and brains were dissected after PBS perfusion and dissociated with the
Adult Brain Dissociation Kit (Miltenyi Biotec, 130-107-677), according to the manufacturer’s protocol. Microglia number was measured by FACS using
CountBright Absolute Counting Beads (Invitrogen, C36950) and diluted to 500 microglia per µl in DPBS + 0.5% BSA. The resulting cell suspension was mixed with pHrodo-green labeled myelin (50 µg ml
−1 in DPBS + 0.5% BSA) or FAM-Aβ (200 nM in DPBS + 0.5% BSA) and incubated at 37 °C for 45 minutes with gentle mixing. Cell suspensions were washed and stained with the following antibodies in FACS buffer (1% fatty acid-free BSA and 1 mM EDTA in PBS) for 25 minutes on ice:
CD11b-BV421 (BioLegend, 101251) and mouse Fc blocker (anti-mouse CD16/32, BioLegend, 101320). Cells were washed with FACS buffer, resuspended in FACS buffer with
propidium iodide (Miltenyi Biotec, 130-93-233), strained through a 100-μm filter and then analyzed on a flow cytometer (
BD FACSAria III). FCS files were then imported and analyzed in FlowJo software (version 10).The percentage of myelin
+ microglia (pHrodo-green
+,
CD11b+) and Aβ
+ microglia (FAM
+,
CD11b+) in the total
CD11b+ microglial population was calculated. See Supplementary Methods for details on myelin debris and Aβ fibril preparation and fluorescent labeling.
van Lengerich B., Zhan L., Xia D., Chan D., Joy D., Park J.I., Tatarakis D., Calvert M., Hummel S., Lianoglou S., Pizzo M.E., Prorok R., Thomsen E., Bartos L.M., Beumers P., Capell A., Davis S.S., de Weerd L., Dugas J.C., Duque J., Earr T., Gadkar K., Giese T., Gill A., Gnörich J., Ha C., Kannuswamy M., Kim D.J., Kunte S.T., Kunze L.H., Lac D., Lechtenberg K., Leung A.W., Liang C.C., Lopez I., McQuade P., Modi A., Torres V.O., Nguyen H.N., Pesämaa I., Propson N., Reich M., Robles-Colmenares Y., Schlepckow K., Slemann L., Solanoy H., Suh J.H., Thorne R.G., Vieira C., Wind-Mark K., Xiong K., Zuchero Y.J., Diaz D., Dennis M.S., Huang F., Scearce-Levie K., Watts R.J., Haass C., Lewcock J.W., Di Paolo G., Brendel M., Sanchez P.E, & Monroe K.M. (2023). A TREM2-activating antibody with a blood–brain barrier transport vehicle enhances microglial metabolism in Alzheimer’s disease models. Nature Neuroscience, 26(3), 416-429.